Agentic AI in Market Access: a New Global Equation for Pharma Market Access Leaders

The pharmaceutical industry has mastered getting therapies approved. Getting them to patients has become the harder challenge.

Market access is now one of the most strategically complex functions in pharma. EU Joint Clinical Assessments, IRA price negotiations, MFN pricing agreements, and outcomes-based contracts are reshaping the operating model at global scale.

The pressure is structural, simultaneous and intensifying.

Yet many organisations still rely on tools built to organise information, not to support complex decisions.

This is where agentic AI changes the equation. By coordinating multi-step workflows across the market access lifecycle, it can monitor payer and HTA developments, generate evidence-based insights, adapt value dossiers, refresh HEOR models, and support pricing and reimbursement decisions in real time.

AI itself is no longer the differentiator. The real advantage lies in the ability to operationalise and scale it across market access.

In our latest white paper, "Agentic AI in Market Access: A New Global Equation for Pharma Market Access Leaders", we examine how market access is evolving, the most relevant agentic AI use cases, and the capabilities required to scale responsibly

Authors:

Dr. Silvia Ondategui Parra, Managing Partner, Global Life Sciences Leader

Gabriele Oliva, BIP xTech Global Life Sciences Director

Nupur Khokher, Manager, Global Life Sciences

Rebecca Attias, Strategy Consultant Intern, Global Life Sciences